日本PDA学術誌 GMPとバリデーション
Online ISSN : 1881-1728
Print ISSN : 1344-4891
ISSN-L : 1344-4891
特集
製薬企業における Part11 対応の課題と展望
池田 静男
著者情報
ジャーナル フリー

2002 年 4 巻 1 号 p. 37-39

詳細
抄録
  It is recommended that organization shall have a reasonable timetable for promptly modifying any systems not in compliance (including legacy systems) to make them Part11 compliant, and shall be able to demonstrate progress in implementing their timetable. The reasons: 1. It takes not so much time to recognize Part11 requiring implementation of secure, computer-generated and time-stamped audit trails etc. as global standard. 2. The Japanese pharmaceutical companies are faces to important phase to decide the implementation of Part11 in their process of globalization. 3. It may take more time to modify the existing systems such as for R&D of new medicine, manufacturing and quality control management of products.
著者関連情報
© 2002 日本PDA製薬学会
前の記事 次の記事
feedback
Top